Trial Profile
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Varlilumab (Primary)
- Indications Colorectal cancer; Fallopian tube cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celldex Therapeutics Inc
- 04 Jan 2019 Status changed from active, no longer recruiting to completed.
- 28 Nov 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
- 07 Nov 2018 According to Celldex Therapeutics media release, Data from the glioblastoma cohort in this study have been accepted for presentation at the Society for Neuro-oncology (SNO) Annual Meeting.